Recently, Puengel et al. revealed that combined therapy with a CCR2/CCR5 antagonist, which blocks the receptor for MCP-1, and an FGF-21 analogue synergizes in ameliorating steatohepatitis and fibrosis in mice subjected to dietary models of NASH and fibrosis [63]. This evidence concerns the gene CCR5 and metabolic dysfunction-associated steatohepatitis.